Technical Data
N0023A
NAP2 (Neutrophil Activating Protein 2, CXCL7, C-X-C motif chemokine 7, PPBP, pro-platelet basic protein)
2ug
10ug
10ug
|
Technical Data |
|
N0023A |
NAP2 (Neutrophil Activating Protein 2, CXCL7, C-X-C motif chemokine 7, PPBP, pro-platelet basic protein) |
2ug 10ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: RT |
|
Recombinant Human NAP-2 is a non-glycosylated, Polypeptide chain containing 70 amino acids and having a molecular mass of 7609 Dalton. Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Ala-Glu-Leu-Arg-Cys Dimers and Aggregates: 1% as determined by silver-stained SDS-PAGE gel analysis. Biological Activity: NAP-2 is fully biologically active when compared to standard. The specific activity as determined by the ability of NAP-2 to chemoattract human neurotrophils using a concentration of 1-10ng/ml. Endotoxin: 0.1ng/ug (IEU/ug) of NAP-2. Protein Content: Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm. 2. Analysis by RP-HPLC, using a standard solution of NAP-2 as a Reference Standard. Reconstitution: Reconstitute the lyophilized NAP-2 in sterile 18M -cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions. Storage and Stability: Lyophilized powder may be stored at 4°C for short-term only. Reconstitute to nominal volume by adding sterile dH2O and store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer. |
Source: E. coli Purity: 98% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. Form: Supplied as a lyophilized powder. No additives. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Relationship between neutrophil-binding affinity and suitability for infection imaging: comparison of (99m)Tc-labeled NAP-2 (CXCL-7) and 3 C-terminally truncated isoforms. Rennen HJ, Frielink C, Zaat SA, J Nucl Med 2004 Jul;45(7):1217-23 2. Chemotactic activity of human blood leukocytes in plasma treated with EDTA: chemoattraction of neutrophils about monocytes is mediated by the generation of NAP-2. Malawista SE, Van Damme J, de Boisfleury Chevance A, J Leukoc Biol 2002 Jul;72(1):175-82 3. The CXC chemokine NAP-2 mediates differential heterologous desensitization of neutrophil effector functions elicited by platelet-activating factor. Schwartzkopff F, Brandt E, Flad HD, J Interferon Cytokine Res 2002 Feb;22(2):257-67 4. Thrombin-activated human platelets release two NAP-2 variants that stimulate polymorphonuclear leukocytes. Piccardoni P, Evangelista V, de Gaetano G, Thromb Haemost 1996 Nov;76(5):780-5 5. Limited and defined truncation at the C terminus enhances receptor binding and degranulation activity of the neutrophil-activating peptide 2 (NAP-2). Comparison of native and recombinant NAP-2 variants. Ehlert JE, Petersen F, Gerdes J, J Biol Chem 1995 Mar 17;270(11):6338-44 6. Neutrophil-activating peptides NAP-2 and IL-8 bind to the same sites on neutrophils but interact in different ways. Discrepancies in binding affinities, receptor densities, and biological effects. Besemer J, J Immunol 1995 Jan 15;154(2):972-4.
|
||